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DPI 201-106 is a new positive inotropic agent. The cardiac electrophysiology of 16 patients was studied before
and during DPI 201-106 administration (loading dose of intravenous DPI 201-106,1-8 mg kg~l h~l admin-
isteredover 10 min, followed by a maintenance dose of 0-2 mg kg~l h~x). DPI 201-106 hadno effect on the
sinus node. The AH interval during fixed-rate atrial pacing became prolonged during DPI 201-106 infusion.
There was a significant prolongation of the QT interval [QT (corrected), 417 ±22 to 502 ±35 ms, P<0-05;
QT (atrialpacing at 600 ms), 374 ±17 to 419 ± 23 ms, P<005;QT(ventricular pacing at 600 ms), 409 ±37
to 449±30 ms, P<0-05J. The ventricular effective refractory period significantly prolonged during DPI
201-106 administration (242 ±21 to 287 ±56 ms, P < 005), but the supernormal-period duration decreased.
The atrial effective refractory period was shortened in four patients and prolonged in one (261 ± 67 to
240 ±53 ms, NS). The corrected atrial repolarization time (PTtc) shortened significantly during DPI 210-
106 infusion (479 ±26 to 445 ±22 ms at 20 min of the maintenance dose, P<0-05). Atrial fibrillation was
initiated in five patients during DPI infusion, but no ventricular arrhythmia was provoked. These findings
suggest that DPI 201-106 has novel differential electrophysiological effects on atria and ventricles.
Introduction the regulation of Na + channels, probably by inter-
DPI 201-106 is a diphenylmethyl-piperazinyl- f e r i n8 w i t h o n e o f i t s ^activators'6'. DPI 201-106
indole derivative with cardiotonic effect which has c a u s e s l a n i n c r e a s e i n mtracellular calcium but does
been demonstrated in vitro"* and in vivo™ in van- ™ l e n i T « ^ l m * " ' £ through slow channels'7!,
ous animals. Its potent inotropic action has also The effect ofDPI 201-106 on.the Na channehmay
been shown in man". DPI 201-106 has a novel inc^M the mtracellularNa load which interferes
mechanism of action which is not related to cAMP, *"* l J e dynamics of the Na /Ca exchange™
to beta-adrenergic or histaminergic receptor stimu- fnd' J ^ ' i n c r e a s e s t h e 'ntracellular calcium
lation, or to the liberation of catecholamines or to a l o a d - T i a s may consequently prolong phase 2 of the
glycoside-likeaction™. There is increasing evidence **™ P°ften, t ial <th,e P l a teau> a " d i n c r e a s e ^ e ava i1"
that this agent modulates Na+ channels and hence ability of calcium for contractile activity. The pro-
affects phase 0 and phase 2 of the cardiac cell action longauon of cardiac action potential ,s, therefore,
potential.Kohlhardt«a/.l«"foundthatDPI201-106 associated with positive inotropic action". Action
prolongedtheconductanceoftheNa+channels,i.e. potential prolongationis reflected by the significant
prolonging the open state. Tetrodotoxin abolishes Prolongation of the QT interval which has been
the effect of DPI 201-106™, hence the inotropic noticed during intravenous administration of DPI
effect of DPI 201-106 is due to its interaction with . , • - . •
The proposed mechanism of action may, there-
o ._• J r ,., , o . , « , J J r -,* fore, influence other electrophysiological par-
Submiued for publication on 19 June 1987 and in revised form 26 ' . . . .
October 1987. ameters of cardiac tissue, as suggested by some
animal experiments'21. The aim of this paper is to
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Cardiological Science?* George's Hospital and Medial School, report the results of a clinical Cardiac eleCtrophySlO-
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Patients and methods
PATIENTS
Sixteen patients (six females), age range 18-76
years (mean 52±15 years), were included in this
study. Of 10 patients, the study was performed as a
part of routine clinical cardiac electrophysiological
evaluation for palpitations in eight, and syncope in
two. The other six patients had 2:1 or complete heart
block and had already been fitted with dual-chamber
pacemakers. None of the patients were on amio-
darone. Other antiarrhy thmic medications were dis-
continued for at least 72 h prior to the study in all
patients. The aims and procedure of the study were
fully explained to each patient and written consent
was obtained. The study was approved by the Ethics
Committee of St Bartholomew's Hospital, London.
ADMINISTRATION OF DPI 201-106
DPI 201-106 was given intravenously according
to the following method: a loading dose of
l-8mgkg~1h~1 was given intravenously over
lOmin (except for the first five patients to whom
0-8—1-5 mgg"1 h"1 were given according to
recommendation of the Ethics Committee). This
was followed immediately by constant infusion of
DPI 201-106 at a dose of 0-2 mg kg" ' h~' for the
entire duration of the study (maintenance dose).
PROTOCOLS
Three protocols were included in this study:
Measurement of intracardiac intervals and
refractoriness
USCI electrode catheters were introduced via the
femoral vein under local anaesthesia (approxi-
mately 10 ml of 1 % lignocaine) and placed to record
and stimulate the right atrium and right ventricular
apex. A tripolar electrode was positioned adjacent
to the His bundle. The intracardiac signals and four
surface electrocardiographic leads (I, aVF, VI and
V6) were recorded simultaneously on a Siemens
Elema mingograph 1600 ink-jet recorder at a paper
speed of 100 mm s"1. Programmed stimulation at
twice the diastolic threshold was performed using a
Bloom stimulator.
Basic intervals were measured, during the load-
ing and maintenance doses in sinus rhythm and dur-
ing constant rate atrial and ventricular pacing (600,
500 and 400 ms) to ± 5 ms accuracy. These intervals
included the following: (a) RR interval, measured
between two consecutive high right atrial electro-
grams; (b) AH interval, between the first rapid
deflection of the low right atrial electrogram and the
start of the His bundle deflection; (c) HV interval
measured from the onset of the His bundle electro-
gram to the earliest ventricular activation on the
surface electrocardiogram; (d) QRS duration,
measured between the earliest and last deflection on
the surface electrocardiogram; and (e) QT interval,
from the earliest deflection of the QRS in the surface
electrocardiogram to the end of the T wave191. The
measured QT intervals during sinus rhythm were
corrected for rate using Bazett's formula'10':
where QTC is the corrected QT interval, QTm is the
measured QT interval, and RR is the RR interval.
The QT intervals were also measured during fixed-
rate atrial pacing (QTJ and fixed rate ventricular
pacing (QTV).
Refractory periods were assessed by pacing (at
twice the diastolic threshold) the high right atrium
(or right ventricular apex) at a constant rate for
eight beats followed by an extra atrial (or ventricu-
lar) paced beat at a decreasing coupling interval.
The following parameters were assessed'"': (a) the
functional atrioventricular nodal refractory period,
which was defined as the shortest distance between
the last His bundle deflection of the atrial driven
cycle and the His deflection following the extra-
stimulus; (b) the effective atrioventricular nodal
refractory period which was defined as the longest
interval between the last atrial deflection of the
driven cycle length and the atrial deflection of any
extra-stimulus beat which failed to result in a His
bundle depolarization; (c) the atrial refractory
period, was the longest interval between the last
atrial driven stimulus and any atrial extra-stimulus
which did not result in atrail depolarization; (d) the
effective ventriculo-atrial refractory period was
assessed by ventricular programmed stimulation —
it was the longest interval between the last ventricu-
lar deflection of the driven cycle length nd the ven-
tricular deflection of any extra-stimulus beat which
failed to result in retrograde conduction to the atria;
and (e) The effective ventricular refractory period
which was defined as the longest interval between
the last ventricular driven stimulus and any extra-
stimulus spike that resulted in no ventricular
depolarization.
Anterograde atrioventricular and retrograde
ventriculo-atrial Wenckebach cycle lengths were
determined by gradually increasing atrial or ven-
tricular pacing rates, respectively until a beat failed
to conduct anterogradely or retrogradely.
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Figure 1 The cathodal strength interval curve, showing the measurements of the super-
normal period in this study. The level of the 5% supernormal-period duration is also
shown. Thm, minimal threshold during supernormal period.
Sinus node function was assessed by pacing the
high right atrium with pacing cycle lengths of 600,
500 and 400 ms, each for 1 min. The longest pause
from the last paced atrial depolarization to the first
sinus return cycle was considered to be the maxi-
mum sinus node recovery time. The maximum
corrected sinus node recovery time was defined as
the longest interval derived by subtracting the
prepacing sinus cycle length from the sinus node
recovery time1'21.
Assessment of ventricular supernormal period
In six patients, cathodal ventricular strength
interval curves were assessed before and during the
maintenance dose of DPI 201-106. The distal pole
of the electrode was used for cathodal stimulation
and the indifferent electrode was placed on the skin.
The high right atrium was paced at a constant rate
of 600 ms for eight beats followed by one ventricu-
lar extra-stimulus. The threshold of the ventricular
extra-stimulus was assessed with 0-01 mA accuracy
using Bloom stimulator at each coupling interval.
The coupling interval of the ventricular extra-
stimulus was decreased until the ventricular pacing
threshold was > 10 mA.
The supernormal period was measured as that
part of the strength interval curve where there was a
5% or more decrease in the threshold below the
diastolic threshold. The period of supernormality in
the cardiac cycle was expressed in relation to the QT
interval (taking Q as 0% and the end of the T wave as
100%). The minimum threshold during the super-
normal period (SNP-Tm) was assessed relative to the
diastolic threshold (Fig. 1).
Assessment of atrial repolarization
Six patients with 2:1 or complete heart block and
who had been fitted with dual chamber pacemakers
were included in this study to assess the atrial
repolarization time (PT.). Standard bipolar
unpaced surface ECG leads I, II and III were
recorded at high fidelity (0-6-30 Hz) and high gain
(x 1000- x 10000) on 0-5 inch magnetic tape before
and during administration of DPI 201-106. The
recording signals were then transferred onto the
computer memory via a 12-bit analogue/digital
converter. The signals were filtered using specially
adapted software1'31. The duration of the P and the
T waves of the atrium (TJ were measured from the
displayed complexes using a high-resolution cross-
hair cursor on a Tectronix 4010 VDU before and
during the loading dose (5 min and 10 min) and
during the maintenance dose (10, 20 and 30 min).
The atrial repolarization duration (PTJ was
corrected according to the following equation1'3':
PT.C = PT.+ 0-29 (1000-RR)
where PT.C is the corrected atrial repolarization
time, PT. is the measured atrial repolarization time,
and RR is the sinus cycle length.
ASSESSMENT OF PLASMA LEVEL
Blood samples (10 ml) were taken immediately
after the loading dose and at 5-10, 15-20 and
25—35 min intervals during the maintenance dose.
Unchanged DPI 201-106 was extracted from
alkalinized plasma into a methyltertbutyl ether/
isopropranol n-hexane mixture and back extracted
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into dilute phosphoric acid. A 500 ul aliquot was
injected directly into a 100 x 21 mm spheri-5 RP-8
column and isocratically eluted with 0-005 M phos-
phoric acid/acetonitrile 35:65 (pH 2-5). Detection
was in the UV range at 228 nm (Smith HT,
unpubl.).
The assay confidence limits (/> = 0-95) over the
whole study concentration range were approxi-
mately ±20% of the expected concentrations as
estimated from calibration and control samples
which had been included in the analysis. Most of
the samples were analyzed twice showing a mean
inter-assay coefficient of variation of less than 10%.
All sample concentrations were above the limit of
detection (10 ng ml)"' .
ANALYSIS OF THE DATA
Mean + SD values were used to express the
dispersion of the data. For statistical inference,
Student's /-test or Wilcoxon's sign ranked test were
used as appropriate. Significance was defined as
/><005.
Results
PLASMA LEVEL OF DPI 201-106
The plasma levels of DPI 201-106 in this study
are shown in Table 1. The plasma concentration
was steady during the maintenance infusion.
Table I
Low*
High*
Plasma level o/DPI201-l(X
Loading
271 ±174
37I-8±264
lOmin
86 ±20
125±45
i (in ngml )
Maintenance
20min
105 ±28
137±67
30min
88 ±20
128±48
*'Low' denotes those patients who had a lower loading dose
(0-8-1-5 mg kg"1 h"1) in compliance with the Ethics Com-
mittee recommendation; 'high' denotes a loading dose of
EFFECT ON BLOOD PRESSURE
There was an increase in the supine systolic blood
pressures during the loading dose of DPI 201-106
(systolic 127±24 to 146±16-3mmHg, f<001) .
Diastolic blood pressures did not show significant
changes (74-4 ± 11 to 88 ± 9 mmHg, NS).
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Figure 2 Changes in the AH interval during different atrial
pacing rates before ( • ) and during (D) the maintenance dose
of DPI 201-106. These changes were statistically significant
(P < 005). The values are represented as mean ± SD.
EFFECT ON SINUS NODE FUNCTION
There was a slight, but statistically insignificant,
increase in the RR intervals after the loading dose of
DPI 201-106 (795±166 to 850±211ms). The
maximum sinus node recovery time changed from
1106 ±28 lms to 948 ± 242 ms (NS), and the
corrected sinus node recovery time decreased from
301±123to231±156ms(NS).
EFFECT ON THE ATRIOVENTRICULAR NODE
There were no changes in the AH intervals in
sinus rhythm during the loading or maintenance
dose of DPI 201-106 (72-5 ± 14 ms). On the other
hand, the AH intervals at constant rate atrial pacing
showed a significant prolongation (P < 005) during
the maintenance dose of DPI 201-106 compared
with the control (Fig. 2).
There was a slight increase in the functional atrio-
ventricular nodal refractory period during the
maintenance dose in four out of six patients in
whom these measurements were possible (413 ±78
to 437 ± 79 ms, NS). It was difficult to assess the
change in atrio-ventricular nodal effective refrac-
tory periods because in four patients these refrac-
tory periods were limited by atrial refractoriness.
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Figure 3 Changes in the atrial effective refractory period
before (B) and during (D) and maintenance dose of DPI 201—
106. These changes were statistically insignificant. The values
are represented as mean ± SD.
In one of the remaining two patients no changes
occurred, but in the other an increase was seen. It
was also difficult to assess the effective refractory
period of ventriculo-atrial conduction because in
two patients it was limited by the ventricular refrac-
tory period and in an additional two patients poor
or no retrograde conduction could be seen. In only
one patient was there a noticeable increase in the
ventriculo-atrial refractory period at the atrio-
ventricular nodal level (480 to 600 ms).
The anterograde Wenckebach cycle length
showed no significant change (377 ±98 to 383 ±
163 ms), neither did the retrograde Wenckebach
cycle length (508 ± 170 ms to 548 ± 147 ms).
EFFECT ON ATRIAL ELECTROPHYSIOLOGY
Refractory period
In four out of six patients who underwent electro-
physiological studies, the atrial refractory period
decreased during the maintenance dose of DPI
201-106. One patient had a marked increase in the
atrial refractory period. The mean value, however,
showed no statistical difference (261 ±67 to
240 ± 53 ms) (Fig. 3).
Atrial PT duration
In six patients who had complete heart block the
corrected atrial repolarization time (PT.C) interval
showed a significant decrease during the mainten-
ance dose particularly after 20 and 30 min
(/"<0-05). These changes were mainly due to
changes in the atrial T-wave duration, as P-wave
duration showed no significant changes (Table 2).
In these patients the corresponding QTC interval
showed a noticeable prolongation (see below).
EFFECT ON VENTRICULAR ELECTROPHYSIOLOGY
HV interval and QRS duration
The HV interval and QRS duration remained
unchanged during both the loading and mainten-
ance infusion of DPI 201-106 at 45 ± 8 ms and
91 ± 12 ms, respectively.
Table 2 Changes (ms) in the surface electrocardiograms of patients with complete heart block before and
during DPI 201-106 administration*
Parameter
PP
P wave
PT.
PT.C
RR
QTe
N
Control
780 ±111
111±8
415±25
479 ±26
I214±144
493 ±49
6
Loading
5 min
846±126
112±11
416±24
460±31
12I0±143
565 ±45
6
lOmin
842±143
U2±6
4O8±19
454 ±33
1208 ±139
574 ±45
6
lOmin
838 ±152
114±5
410±14
457 ±32
1203 ±156
549±51
5
Maintenance
20 min
915±13O
116±5
416± 14
445 ±22
1263 ±57
572 ±49
4
30 min
874±140
116±7
411 ± 12
447±31
1246 ± 67
567 ±56
3
*For abbreviations see text.
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Figure 4 Changes in the ventricular effective refractory
period before (B) and during (D) the maintenance dose of
DPI 201-106a. These changes were statistically significant
(P < 005). The values are represented as mean ± SD.
Ventricular effect refractory period
There was a significant increase in the ventricular
effective refractory period in six out of nine patients
studied during the maintenance infusion of DPI
201-106 as estimated by extra-stimulus technique
(242 ± 21 ms to 287 ± 56 ms, P < 005). This increase
was also seen in all six patients in whom the
cathodal strength interval curve was assessed
(300±25msto333±31ms/><001)(Fig. 4).
QT interval
Corrected QT intervals showed a significant in-
crease after the loading dose of DPI 201-106
(417±22msto502±35ms, ^<005)(Fig. 5). This
increase was also evident during the constant rate
atrial or ventricular pacing (Fig. 6).
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Figure 5 Changes in QTC during the loading dose of
DPI 201-106. These changes were statistically significant
(/><005). B, before drug administration. The values are
represented as mean ± SD.
Effect on ventricular supernormal period
DPI 201-106 had no effect on the ventricular
diastolic cathodal threshold. The supernormal
period could be demonstrated in five of six patients
during DPI 201-106 infusion. The minimum thres-
hold during the supernormal period (SNP-Tm) sig-
nificantly increased (/><005) (Table 3); but the
supernormal-period duration decreased (/ )<005,
Table 3) during DPI 201-106 infusion. The relation
of the supernormal to the atrially paced QT interval
showed that, during DPI 201-106 infusion, there
was a significant shift in the position (/)<0-05,
Table 3) away from the peak of the T wave. The
upper limit shifted from 133±8% to 121 ±19%,
but these were not significant (Table 3).
EFFECT ON CARDIAC ARRHYTHMIAS
There was no ventricular proarrhythmic effect of
DPI 201-106. In one patient with ventricular tachy-
cardia, the tachycardia was still provokable during
the infusion. In five patients, however, DPI 201-106
appeared to facilitate the provocation of atrial
fibrillation. In three of these patients the atrial
fibrillation was provoked by atrial extra-stimulus
near the atrial refractory period. Two of these had a
history of paroxysmal atrial fibrillation. In two
patients, atrial fibrillation was spontaneous and
lasted for 2—4 h: one had a history of paroxysmal
atrial fibrillation and the other a congenital
atrio-ventricular block.
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Figure 6 Changes in the atrially paced QT interval (QTJ and ventricularly paced QT interval
(QT,) before ( • ) and during (D) the maintenance dose of DPI 201-106. The differences were
significant (P < 005). The values are represented as mean ± SD.
Table 3 Cathodal supernormal period*
Parameter Control During DPI
Diastolic threshold (mA)
SNP-Tm (%)
5% duration (ms)
5% position (%)
0-49 ±0-30
16±10
155±76
85±11-133±8
0-46±0-27
9±9
79 ±42
97± 14-121 ± 19
•For abbreviations and details see text.
Discussion
DPI 201-106 demonstrates a novel spectrum of
electrophysiological effects which may reflect on its
mechanism of action. The most remarkable effects
were on ventricular electrophysiological par-
ameters. The marked prolongation of the QT inter-
val and the increase in ventricular refractory period,
as documented in this and other studies'21, may be
explained by the prolongation of action-potential
duration produced by DPI 201-106121, possibly due
to the agonistic effect of DPI 201-106 on the Na +
channel as explained above. The effect of DPI 201—
106 on the supernormal period is of particular
interest. There are, to our knowledge, no studies on
the effect of DPI 201-106 on the cellular action
potential supernormal period. The clinically
assessed supernormal period of the ventricle is
thought to be dependent on the dispersion of the
action-potential duration'141. The decrease in the
duration of the supernormal period during DPI
201-106 infusion in this study may be due to pro-
longation of the cellular action potentials leading to
a decrease in their dispersion. The fact that super-
normal periods were shifted towards the end of the
T waves supports this explanation.
The effect of DPI 201-106 on atrial electro-
physiology is of particular interest. Contrary to the
effect on the ventricles, there was a decrease in the
atrial effective refractory period in four out of six
patients studied. This observation was consoli-
dated by the observation that the corrected atrial
repolarization time (PT,C) was also shortened. The
measurement of PT,C in patients with heart block
has been described previously1'31 and, in general, the
PT.C behaves in a similar way to the ventricular QTC
interval. DPI 201-106 prolongs the action potential
duration in the isolated rabbit atria'11. It is, there-
fore, difficult to attribute the findings of this study
to a direct effect of DPI 201-106. A reflex mechan-
ism may be an alternative explanation. Cholinergic
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fibres selectively innervate atrial tissue1'51. An
increase in the vagal tone by baroreceptor stimu-
lation may decrease the effective atrial refractory
period1'61. The increase in systolic blood pressure
during DPI 201-106 infusion may trigger baro-
receptor activity and, thereby, increase vagal
activity. The high incidence of induced atrial fibril-
lation in this study may also be explained by a
possible increase in vagal tone1'71. Some support for
this view come from Walker et al.[lg] who noticed
that DPI 201-106 significantly prolonged the sinus
cycle length, sinus node recovery time, atrio-
ventricular nodal functional refractory period,
right ventricular functional refractory period and
the QT interval. These findings could not be
reproduced in cardiac transplanted dogs.
DPI 201-106 does not show a significant effect on
the sinus node. The slight slowing of the sinus rate
did reach statistical significance. This finding is not
consistent with the hypothesis of increased vagal
tone. If this hypothesis is correct, then DPI 201-106
must decrease the sensitivity of the sinus node to
vagal effects. The atrio-ventricular nodal conduc-
tion during sinus rhythm did not alter during DPI
201-106 infusion; however, there was a slight, but
significant, prolongation during fixed-rate atrial
pacing. The atrio-ventricular nodal functional
refractory period also increased slightly. These
findings are consistent with the hypothesis of
increased vagal activity. The agonostic effect of DPI
201-106 on the Na+ channel and its consequent
influence on the action potential duration may not
be applied to atrio-ventricular nodal tissues because
they depend mainly on the Ca2+ channel. Recently,
it was found that DPI 201-106 has a calcium
antagonistic effect with prolonged treatment1"1. It is
therefore not clear whether the electrophysiological
effects seen in this study will be applicable to long-
term treatment.
It should be mentioned that two different loading
doses were used in this study. This was at the request
of the Ethics Committee of St Bartholomew's
Hospital. The recommendation was that the first
four patients should receive a lower loading dose
before proceeding to the loading dose of
l-Smgkg"1 h"1 as originally intended. However,
the same effects were observed in the first four
patients as in the rest of the patients. Because of the
number of the patients, the pattern of the study and
the doses' used, it was not possible to assess dose
response. Recently, it has been suggested that DPI
201-106 has some antiairhythmic effects'201. This
study was not designed to assess this possibility. On
the other hand, DPI 201-106 facilitated the initi-
ation of atrial fibrillation in five patients. In one
patient with ventricular tachycardia, DPI 201-106
did not change the electrophysiological pattern of
that arrhythmia.
In conclusion, DPI 201-106 has an interesting
and novel spectrum of electrophysiological effects
which may be important during the routine clinical
use of this agent.
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